As of November 6, 2026, Protalix BioTherapeutics, Inc. is a publicly traded company (NYSE: PLX); its largest reported holder is HOLD Alapkezelo Zrt., with 5.2% on Schedule 13G of October 15, 2026, then BlackRock (5.02%). The largest insider holding is Dror Bashan, the chief executive and president, with 2,532,934 shares (3.1% of shares outstanding), per Form 4 of December 23, 2025 (Schedule 13G, October 15, 2026).
Is this your company?
About to sign with, pay or invest in Protalix BioTherapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Protalix BioTherapeutics, Inc. a real, registered company?
- Protalix BioTherapeutics, Inc. files with the SEC under CIK 1006281 (its SEC filings).
- Its shares are listed under the ticker PLX on NYSE (SEC company record).
- Incorporated in Delaware; business address in Hackensack, New Jersey, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Protalix BioTherapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names HOLD Alapkezelo Zrt. (filed 2026-10-15).
Who are Protalix BioTherapeutics, Inc.'s owners and officers?
Protalix BioTherapeutics, Inc.: incorporated in Delaware; business address in Hackensack, New Jersey; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-15).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-15 | Hold Alapkezelo Zrt. | 5.2% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.02% |
| Schedule 13G/A, 2026-03-30 | Mak Capital Fund LP | 4.5% |
| Schedule 13G, 2026-03-04 | Mak Capital Fund LP | 5.8% |
Questions about who owns Protalix BioTherapeutics, Inc.
Who owns Protalix BioTherapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Protalix BioTherapeutics, Inc.: Hold Alapkezelo Zrt. (5.2%, Schedule 13G, filed 2026-10-15) and Blackrock, Inc. (5.02%, Schedule 13G, filed 2026-07-29).
Who are the largest shareholders of Protalix BioTherapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Protalix BioTherapeutics, Inc. on this page are Hold Alapkezelo Zrt. (5.2%) and Blackrock, Inc. (5.02%).
When did Hold Alapkezelo Zrt. buy into Protalix BioTherapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Hold Alapkezelo Zrt. on this page is the Schedule 13G, filed 2026-10-15, reporting 5.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Protalix BioTherapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Protalix BioTherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Protalix BioTherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Protalix BioTherapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 2,532,934 shares (3.1% of shares outstanding), 188,516 held directly and 2,344,418 indirectly (Form 4, 2025-12-23).
- , the chief financial officer and senior vice president: 660,909 shares (0.82% of shares outstanding), held indirectly through a trust (Form 4/A, 2024-11-05).
- , a director: 310,500 shares (0.39% of shares outstanding), 303,000 held directly and 7,500 indirectly (Form 4, 2025-09-04).
- , the senior vice president and operations: 232,929 shares (0.29% of shares outstanding), 7,112 held directly and 225,817 indirectly (Form 4, 2025-09-04).
- , a director: 7,500 shares (0.01% of shares outstanding), held indirectly through a trust (Form 4, 2025-09-04).
Shares outstanding: 80,571,642 as of 2026-08-01, from the company's latest SEC cover page.
How much has Protalix BioTherapeutics, Inc. raised?
No fundraising or offering filing from Protalix BioTherapeutics, Inc. is on file with us.
Keep reading
More on Protalix BioTherapeutics, Inc. and the records around it.
Protalix BioTherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
Companies that share a holder
- HOLD Alapkezelo Zrt. also filed stake reports on 2 other companies: PERMA FIX ENVIRONMENTAL SERVICES INC (Oct 2026), MediWound Ltd. (Aug 2026)
- MAK Capital Fund LP also filed stake reports on 7 other companies: Comstock Inc. (Oct 2026), Autolus Therapeutics plc (May 2026), ClearPoint Neuro, Inc. (May 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/protalix-biotherapeutics